Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 343

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial

Noronha, Vanita, Joshi, Amit, Patil, Vijay Maruti, Agarwal, Jaiprakash, Ghosh-Laskar, Sarbani, Budrukkar, Ashwini, Murthy, Vedang, Gupta, Tejpal, D’Cruz, Anil K., Banavali, Shripad, Pai, Prathamesh S., Chaturvedi, Pankaj, Chaukar, Devendra, Pande, Nikhil, Chandrasekharan, Arun, Talreja, Vikas, Vallathol, Dilip Harindran, Mathrudev, Vijayalakshmi, Manjrekar, Aparna, Maske, Kamesh, Bhelekar, Arati Sanjay, Nawale, Kavita, Kannan, Sadhana, Gota, Vikram, Bhattacharjee, Atanu, Kane, Shubhada, Juvekar, Shashikant L., Prabhash, Kumar · 2018 · Journal of Clinical Oncology

Abstract

Purpose: Chemoradiation with cisplatin 100 mg/m 2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a-week cisplatin is substituted because of perceived lower toxicity and convenience. However, there is no level 1 evidence of comparable efficacy to cisplatin once every 3 weeks. Patients and Methods: In this phase III randomized trial, we assessed the noninferiority of cisplatin 30 mg/m 2 given once a week compared with cisplatin 100 mg/m 2 given once every 3 weeks, both administered concurrently with curative intent radiotherapy in patients with LAHNSCC. The primary end point was locoregional control (LRC); secondary end points included toxicity, compliance, response, progression-free survival, and overall survival. Results: Between 2013 and 2017, we randomly assigned 300 patients, 150 to each arm. Two hundred seventy-nine patients (93%) received chemoradiotherapy in the adjuvant setting. At a median follow-up of 22 months, the estimated cumulative 2-year LRC rate was 58.5% in the once-a-week arm and 73.1% in the once-every-3-weeks arm, leading to an absolute difference of 14.6% (95% CI, 5.7% to 23.5%); P = .014; hazard ratio (HR), 1.76 (95% CI, 1.11 to 2.79). Acute toxicities of grade 3 or higher occurred in 71.6% of patients in the once-a-week arm and in 84.6% of patients in the once-every-3-weeks arm ( P = .006). Estimated median progression-free survival in the once-a-week arm was 17.7 months (95% CI, 0.42 to 35.05 months) and in the once-every-3-weeks arm, 28.6 months (95% CI, 15.90 to 41.30 months); HR, 1.24 (95% CI, 0.89 to 1.73); P = .21. Estimated median overall survival in the once-a-week arm was 39.5 months and was not reached in the once-every-3-weeks arm (HR, 1.14 [95% CI, 0.79 to 1.65]; P = .48). Conclusion: Once-every-3-weeks cisplatin at 100 mg/m 2 resulted in superior LRC, albeit with more toxicity, than did once-a-week cisplatin at 30 mg/m 2, and should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.74.9457

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 343

Metadata

Authors
Noronha, V., Joshi, A., Patil, V. M., Agarwal, J., Ghosh-Laskar, S., Budrukkar, A., Murthy, V., Gupta, T., D’Cruz, A. K., Banavali, S., Pai, P. S., Chaturvedi, P., Chaukar, D., Pande, N., Chandrasekharan, A., Talreja, V., Vallathol, D. H., Mathrudev, V., Manjrekar, A., Maske, K., Bhelekar, A. S., Nawale, K., Kannan, S., Gota, V., Bhattacharjee, A., Kane, S., Juvekar, S. L., & Prabhash, K.
Venue
Journal of Clinical Oncology
Published
2018-04-10
Volume
36
Issue
11
Pages
1064-1072
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2771191081
Cited by
343
References
20
FWCI
26.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.